Rectal prolapse means the rectum loses its usual position: an external prolapse can pass through the anus, while internal prolapse folds within the rectum. Confidence is high that the anatomy and bowel symptoms need clinical assessment before choosing treatment. Constipation care can reduce strain, but this review does not establish a supplement that repairs prolapse or one operation suitable for everyone. External prolapse; Internal and external types.
- External full-thickness prolapse, mucosal prolapse and internal folding are different findings.
- A rectocele is a bulge toward the vagina and needs its own assessment.
- The care plan should address bowel emptying and leakage as well as the bulge.
- Surgical decisions depend on anatomy, medical fitness, previous operations and patient goals.
- A trapped prolapse that cannot return inside needs emergency assessment.
- An NHS label or research-foundation grant does not clear every underlying trial’s finances.
Table of contents
- Evidence summary
- What is rectal prolapse? External, mucosal and internal types
- Why prolapse causes symptoms and how assessment guides care
- Treatment: conservative care, perineal repair and rectopexy
- Constipation, fibre and supplements: support without a repair claim
- Which operation works best? What the original trial can show
- Emergency signs, mesh complications and surgical risks
- Medicines, fibre and rectal products around surgery
- Who needs particular care: frailty, pelvic symptoms and children
- Clinician-led decisions, recovery and follow-up
- Why laboratory and animal findings cannot establish repair
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Different prolapse anatomies | External types; Internal folding | Public education/provider income traced; trials not all cleared | High confidence in terminology; examination must connect anatomy and symptoms. |
| Conservative bowel support | Bowel-function review; Constipation context | Provider Tier 2 and national public education | Clinical support; no guaranteed anatomical reversal claim. |
| Internal ventral mesh rectopexy | 2018 restricted guidance | NICE institution Tier 2; complete panel/trial finance unclassified | Special governance, consent, selection and audit/research; January 2026 migration unchanged. |
| DELORES operation comparison | Original 2025 report | DFG grant; indirect backer chain and full project finances not cleared | Qualified selected-population context; no universal independent best-operation verdict. |
| Anatomical repair supplements | No financially cleared human benefit established here | Seller claims and mechanistic extrapolation excluded | A stool change or laboratory mechanism does not prove durable repair. |
What is rectal prolapse? External, mucosal and internal types
Full-thickness external prolapse involves the whole rectal wall protruding through the anus. Mucosal prolapse involves the lining. Internal prolapse, also called rectal intussusception, folds inside and may not produce an external bulge. These descriptions should be confirmed clinically rather than assigned from an internet photograph. External terminology; Internal folding.
A rectocele involves the rectum bulging into the back vaginal wall. Pelvic-organ problems can coexist, but the names are not interchangeable. Tell the clinician whether the bulge is anal or vaginal and whether there are bladder or sexual symptoms. Pelvic-organ anatomy.
An anal lump or bleeding can have another cause. Seeking examination is more useful than assuming that every protrusion is prolapse, haemorrhoids or cancer. The point of the assessment is to connect the observed anatomy with the symptoms that need treatment.
Why prolapse causes symptoms and how assessment guides care
Symptoms can include mucus, a protruding bulge, discomfort, leakage and incomplete emptying. Chronic constipation, vaginal childbirth, heavy lifting and weak pelvic support can be associated with it, but their presence does not establish the cause in one person. Symptoms and associated factors.
Describe when the bulge appears, whether it returns inside, stool consistency, urgency, leakage, straining and any need to assist emptying. Mention bleeding, pain and prior pelvic operations. Distinguish the symptom you most want improved from the anatomical finding a clinician has described.
For complex pelvic-floor symptoms, coordinated assessment can involve colorectal surgery, urogynaecology, physiotherapy and other specialists. Ask whether a proposed examination or imaging study will clarify external versus internal prolapse, another pelvic problem or bowel function. A test is useful when it answers a question that changes the plan. Multidisciplinary service context.
Treatment: conservative care, perineal repair and rectopexy
A clinician may first address bowel habit and offer specialist instruction on toilet technique and pelvic-floor function. This can support symptom management without proving that exercises reverse every anatomical prolapse. Rectal irrigation, when appropriate, requires a specialist plan; it is not an instruction to insert a home device. Bowel-function assessment.
Perineal operations work through the anal region. Delorme’s operation removes the prolapsed lining; an Altemeier procedure removes a prolapsed bowel segment and reconnects it. The actual procedure and anaesthetic require assessment of the person and prolapse. Perineal surgical context.
Ventral mesh rectopexy secures the rectum through an abdominal approach using mesh. Ask the surgeon to explain the proposed material, alternatives and long-term considerations. Mesh approach.
For INTERNAL prolapse, NICE calls for special governance, consent and audit/research arrangements, multidisciplinary selection and appropriately experienced surgeons. The January 2026 move to HTG475 left its 2018 recommendations unchanged. That date must not be presented as a new positive trial review. Restricted recommendations; Administrative update.
Constipation, fibre and supplements: support without a repair claim
A bowel plan should aim for comfortable emptying and avoid persistent straining. Appropriate fibre, fluid intake and activity depend on stool pattern and other medical needs; increasing fibre rapidly can cause bloating. Ask how to judge whether the change is helping rather than escalating several products at once. Constipation care.
Laxative classes act differently and have their own precautions. The choice should reflect the assessment, including the possibility of obstruction or a postoperative restriction. This guide gives no personal laxative dose or combination. A watery bowel movement after a product does not show that the prolapse has been corrected. Laxative classes and cautions.
No financially cleared human evidence reviewed here establishes probiotics, vitamins, collagen powders or a herbal “pelvic support” mixture as anatomical prolapse repair. A claimed mechanism cannot substitute for relevant clinical outcomes. Supplement formulations may also differ, and safety alongside medicines or surgery is not automatically known. Supplement limits.
Discuss practical support for leakage, discomfort, toilet access and work while awaiting specialist review. A manageable bowel plan can be worthwhile even when further anatomical treatment is needed; its success should be judged separately from the size or position of the prolapse.
Which operation works best? What the original trial can show
The 2025 DELORES report compared laparoscopic resection rectopexy with Delorme’s procedure in selected patients suitable for both. It found lower recurrence with resection rectopexy. Seventy people were randomised and 65 analysed; recruitment targets changed, follow-up involved censoring and blinding was incomplete. It did not compare all mesh approaches or establish the best choice for very frail patients. Original trial and limits.
Its funding and broader backer chain are disclosed below, so it is retained as qualified context rather than a fully cleared independent surgical ranking. Applying one study to a different anatomy, previous repair or medical risk can turn a useful result into a misleading promise.
Ask about recurrence, constipation, leakage, pain, sexual function and the need for additional treatment. Technical correction, symptom improvement and a complication-free recovery are separate outcomes. Ask how long the quoted follow-up lasted and whether the surgeon’s figures concern patients with a prolapse like yours.
North Tees’ leaflet duplicates a recurrence label beside different estimates. Those numbers are omitted; a recent date does not resolve the ambiguity. Leaflet reporting limitation.
Emergency signs, mesh complications and surgical risks
A prolapse trapped outside that cannot return inside can lose its blood supply and requires emergency treatment. Do not wait for a routine appointment or force a painful bulge back using a generic technique found online. Trapped-prolapse warning.
Non-stop bleeding, a large amount of blood or large clots needs emergency help. Black or dark-red stool and bloody diarrhoea need urgent assessment. Existing prolapse does not explain away a changed bleeding symptom. Bleeding triage.
Perineal repair can involve bleeding, narrowing, recurrence, continued leakage and a bowel-join leak that may be serious. Consent should cover the particular operation rather than a generic statement that minimally invasive surgery is safe. Perineal repair risks.
Mesh can erode into surrounding tissue years later and may require complex further surgery. Ask how future symptoms will be investigated, who retains the implant record and how long follow-up will last. The absence of an early wound problem does not exclude every later implant complication. Mesh-related harms.
After perineal repair, abdominal pain, foul-smelling discharge or fever warrants prompt contact with the surgical team or urgent assessment. Obtain the team’s written escalation plan before going home. Postoperative warning signs.
Medicines, fibre and rectal products around surgery
Ispaghula can alter absorption of medicines, including lithium, carbamazepine, digoxin, diabetes medicines and mesalazine. Give the pharmacist the full medicine/supplement list and follow product-specific spacing advice rather than a universal rule from this article. Fibre interaction information.
A surgical pre-assessment should review general health, medicines and anaesthetic suitability. Ask for exact instructions concerning blood thinners, diabetes treatments and supplements; do not stop an essential medicine by yourself or copy another patient’s bowel preparation. Individual pre-assessment.
Some supplements can affect bleeding or anaesthesia. Provide labels as well as brand names, since ingredients and concentrations can vary. “Natural” does not establish perioperative compatibility. Surgical supplement disclosure.
After a repair, rectal medicines, enemas or irrigation may interfere with recovery and need the surgeon’s approval. A bowel-emptying technique previously taught before surgery should not be restarted automatically after it. Rectal-product precautions.
Who needs particular care: frailty, pelvic symptoms and children
Medical fitness, anaesthetic risk and previous operations matter when discussing repair. Age alone cannot select a procedure. Ask what the proposed operation aims to improve and which risks are especially relevant to the person being assessed. Health and anaesthetic assessment.
Vaginal bulging, bladder problems, difficult emptying or painful sex may require coordinated pelvic-floor review. Treating one anatomical compartment is not a promise to resolve every symptom. Explain the full symptom pattern rather than withholding it because the appointment is labelled colorectal. Overlapping pelvic symptoms; Coordinated care.
Rectal prolapse also occurs in children, where causes and management differ. Constipation or another underlying condition may need assessment. Adult operation comparisons, bowel preparation and laxative instructions should not be reused for a child; a trapped prolapse still needs emergency care. Childhood context.
Pregnancy, limited mobility and support needs should be raised early so assessment and recovery are workable. Ask who will help with transport, toilet access and written instructions. These needs are part of treatment planning, not a reason to ignore a new warning symptom.
Clinician-led decisions, recovery and follow-up
Bring a symptom diary, medicine list and records of previous repairs. Ask the clinician to name the anatomy clearly: full-thickness external, mucosal, internal folding, rectocele or a combination. Then ask which finding plausibly explains the symptoms and what remains uncertain.
If an operation is proposed, discuss alternatives, implant details, recurrence, functional outcomes and the possibility of additional treatment. For internal mesh rectopexy, ask how the NICE governance and consent requirements are met and how outcomes are recorded. Consent and audit context.
Obtain your own fasting, preparation, pain-control, bowel-care and activity instructions. Recovery and return to work vary with the operation and the person. The cited provider advises follow-up and individual recovery support; its timetable is not a personal prescription for every procedure. Recovery context.
Agree who to contact for renewed bulging, difficult emptying, leakage or pain. Review symptoms and daily function as well as the surgical examination. This guide provides no manual reduction technique, enema volume, irrigation programme or personal medicine schedule.
Why laboratory and animal findings cannot establish repair
Animal mesh-integration studies, laboratory collagen measurements and supplement effects on isolated tissue cannot establish a lasting prolapse repair in people. A material’s mechanical strength also does not prove acceptable pain, infection, erosion or bowel function over years.
Animal and in-vitro evidence is excluded from the treatment verdict. Useful human studies should specify the anatomy, comparator, patient fitness, symptom outcomes, recurrence, harms and follow-up. The funding review must include supplied products, investigator ties and backers of apparently public research organisations.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 17 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The two NHS providers have their own private-patient, research and charitable income chains. These do not prove that a maker paid for a particular leaflet, but national public-service branding cannot substitute for tracing the provider. The source table records actual dates and visible reporting gaps.
DELORES names DFG grant PO 342/3-1. DFG’s original institutional statement identifies public governments and Stifterverband, whose own membership page describes company and other supporters. The origin of every project contribution is not known. No particular manufacturer is invented as the trial sponsor; its complete chain remains unclassified.
NICE’s committee and underlying studies are also not all financially cleared. Corporate efficacy is excluded from the independent verdict. Provisional grades describe incentives and uncertainty, not an allegation that a source’s data were fabricated.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NIDDK: rectal prolapse | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | C, provisional — public scientific review; August 2019 age, simplified care and unverified page-level expert/trial finances limit current efficacy conclusions. |
| Guy’s and St Thomas’: Perineal repair overview | Own 2025–2026 accounts: NHS care, private-patient, commercial research and charitable income. Leaflet-level maker payment not established. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 provider, provisional; indirect care/private/research interests. | B, provisional — November 2024 local specialist information and statutory accountability; service incentives, simplification and uncleared underlying trials. |
| Guy’s and St Thomas’: Perineal repair surgery | Own 2025–2026 accounts: NHS care, private-patient, commercial research and charitable income. Leaflet-level maker payment not established. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 provider, provisional; indirect care/private/research interests. | B, provisional — November 2024 local specialist information and statutory accountability; service incentives, simplification and uncleared underlying trials. |
| Guy’s and St Thomas’: Perineal repair recovery | Own 2025–2026 accounts: NHS care, private-patient, commercial research and charitable income. Leaflet-level maker payment not established. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 provider, provisional; indirect care/private/research interests. | B, provisional — November 2024 local specialist information and statutory accountability; service incentives, simplification and uncleared underlying trials. |
| Guy’s and St Thomas’: Rectocele care | Own 2025–2026 accounts: NHS care, private-patient, commercial research and charitable income. Leaflet-level maker payment not established. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 provider, provisional; indirect care/private/research interests. | B, provisional — January 2025 local specialist information and statutory accountability; service incentives, simplification and uncleared underlying trials. |
| Guy’s and St Thomas’: Pelvic-floor service | Own 2025–2026 accounts: NHS care, private-patient, commercial research and charitable income. Leaflet-level maker payment not established. | United Kingdom; Guy’s and St Thomas’ NHS Foundation Trust, London. | Tier 2 provider, provisional; indirect care/private/research interests. | B, provisional — July 2025 local specialist information and statutory accountability; service incentives, simplification and uncleared underlying trials. |
| North Tees and Hartlepool: ventral mesh rectopexy | Own 2024–2025 accounts: NHS care, private/overseas care, research, charity and subsidiary income. Maker payment for this leaflet not established. | United Kingdom; North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees/Hartlepool. | Tier 2 provider, provisional; indirect institutional interests. | C, provisional — reviewed 29 September 2026; duplicated recurrence labels, service incentives and incomplete trial finances limit numerical claims. |
| NICE HTG475: recommendations | Own 2025–2026 accounts: mainly DHSC grant, NHS England support, appraisal/advice fees and research income. Committee and supporting trial finances not cleared. | United Kingdom; NICE London/Manchester; national care/payer remit. | Tier 2 institution, provisional; panel/trial financing unclassified. | B, provisional for accountable guidance process — restricted evidence explicitly acknowledged; 2018 clinical basis, cost remit and commercial service income remain limits. |
| NICE HTG475: update information | Own 2025–2026 accounts: mainly DHSC grant, NHS England support, appraisal/advice fees and research income. Committee and supporting trial finances not cleared. | United Kingdom; NICE London/Manchester; national care/payer remit. | Tier 2 institution, provisional; panel/trial financing unclassified. | B, provisional for accountable guidance process — restricted evidence explicitly acknowledged; 2018 clinical basis, cost remit and commercial service income remain limits. |
| DELORES: original 2025 randomised trial | DFG Clinical Trial Funding Program, PO 342/3-1. A no-conflict declaration is reported; complete author/institution procurement chain not verified. DFG backers include public governments and Stifterverband. | Germany/Switzerland; academic surgical centres; DFG Bonn, Germany. | Tier 2 indirect funder context, provisional; full project chain unclassified. | C, provisional — randomisation and some blinded assessment help; selected fit patients, recruitment change, censoring and incomplete finances limit a universal surgical verdict. |
| DFG: original 2024 institutional funding statement | Own publication identifies mostly federal/state government funding plus Stifterverband contributions. Specific origin of every DELORES grant euro not established. | Germany; German Research Foundation, Kennedyallee 40, Bonn. | Tier 3 financial self-report; institution has Tier 2 indirect private-backer context. | B, provisional for provenance — explicit backer identification; 2024 document, research-policy interests and incomplete project allocation. |
| DFG: current annual-report landing page | DFG institutional publication; latest listed report concerns 2025. Backer chain is documented separately in its original statement. | Germany; DFG Bonn; projects can involve other countries. | Tier 3 institutional self-report; indirect private-backer context remains. | B, provisional for report/date context — self-published activity reporting; research volume is not proof of a trial’s independence. |
| Stifterverband: original membership and support page | Membership fees and donations from companies, foundations, organisations and individuals; specific member money reaching DELORES not identified. | Germany; legal seat/address Essen, verified in its separate imprint. | Tier 3 advocacy/self-report; corporate member/backer relationships. | C, provisional for independence — openly supports research/education policy with business-linked backers; no proof a named maker funded this trial. |
| Stifterverband: legal imprint | The same member/donation-supported association; legal disclosure does not audit allocation of contributions. | Germany; Stifterverband für die Deutsche Wissenschaft e.V., Baedekerstraße 1, Essen. | Tier 3 organisation self-report; backer interests described separately. | B, provisional for identity — registered legal details; not financial or clinical independence certification. |
| NHS: pelvic organ prolapse | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: constipation | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: laxatives | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: rectal bleeding | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | C, provisional — public care accountability supports triage; last reviewed 12 April 2023, with the 12 April 2026 review due date passed. Simplification and page/expert/trial finances remain limits. |
| NHS: ispaghula interactions | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NCCIH: supplement safety | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
Frequently asked questions
Is internal prolapse the same as a visible bulge? No. Internal folding may stay within the rectum. Anatomical distinction.
Is a rectocele the same condition? It is a bulge toward the vagina and can coexist with other pelvic problems. Pelvic-organ distinction.
Can fibre or supplements repair prolapse? Bowel care may help symptoms, but this review establishes no supplement-based anatomical repair. Supportive bowel care.
Does surgery guarantee normal bowel control? No. Discuss residual leakage, recurrence and other risks for the actual procedure. Consent context.
When is prolapse an emergency? A trapped prolapse that cannot return inside needs emergency assessment. Emergency complication.
Sources and funding notes
Clinical context is mainly UK NHS/NICE and US NIDDK; DELORES recruited selected German/Swiss patients in 2010–2016 and was reported in 2025. NIDDK is August 2019; Guy’s and St Thomas’ perineal pages November 2024 and rectocele January 2025; North Tees’ leaflet was reviewed 29 September 2026. Its duplicated recurrence labels are not reproduced. NICE recommendations are 2018 and the January 2026 move was administrative; indexed originals were used after direct 403. Provider accounts concern different years, not a generic NHS funding profile. DFG’s backer statement is from 2024; its current annual-report landing page lists 2025. Corporate-supported efficacy, animals and laboratory findings are excluded from the independent verdict; the complete finance of every supporting trial is not known.
- NIDDK: rectal prolapse — Full-thickness/mucosal terminology, childhood context and trapped-prolapse emergency; not current procedure ranking.
- Guy’s and St Thomas’: Perineal repair overview — Symptoms, conservative assessment and general surgical risks.
- Guy’s and St Thomas’: Perineal repair surgery — Delorme/Altemeier procedural and pre-assessment context; no home preparation schedule.
- Guy’s and St Thomas’: Perineal repair recovery — Individual recovery, rectal-product caution and postoperative escalation.
- Guy’s and St Thomas’: Rectocele care — Bowel-function assessment and distinct vaginal symptoms; imprecise anatomical wording not copied.
- Guy’s and St Thomas’: Pelvic-floor service — Multidisciplinary care context; not outcome evidence.
- North Tees and Hartlepool: ventral mesh rectopexy — Internal/external anatomy, mesh procedure and harms; conflicting recurrence figures omitted.
- NICE HTG475: recommendations — 2018 guidance for INTERNAL prolapse; special governance/consent/audit and multidisciplinary selection. Indexed original after direct 403.
- NICE HTG475: update information — January 2026 administrative move from IPG618; recommendations unchanged, not a new evidence review.
- DELORES: original 2025 randomised trial — Qualified comparative context only; not a financially cleared best-operation recommendation.
- DFG: original 2024 institutional funding statement — Trace trial funder beyond its public-research label.
- DFG: current annual-report landing page — Verify report year; no annual-income number or efficacy claim adopted.
- Stifterverband: original membership and support page — Trace the DFG’s additional backer; do not invent a project-specific sponsor.
- Stifterverband: legal imprint — Verify legal organisation and headquarters/address.
- NHS: pelvic organ prolapse — Rectocele anatomical distinction and coexisting vaginal/bladder symptoms.
- NHS: constipation — Bowel-habit assessment and non-prescriptive supportive care.
- NHS: laxatives — Class differences, suitability and adverse effects; no personal regimen.
- NHS: rectal bleeding — Urgent heavy/non-stop bleeding and black/dark-red stool triage.
- NHS: ispaghula interactions — January 2026 absorption and medicine-combination cautions.
- NCCIH: supplement safety — Product differences, perioperative disclosure and incomplete special-population safety; not anatomical repair evidence.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
